. Author manuscript; available in PMC: 2018 May 1.

Published in final edited form as: Cancer Causes Control. 2017 Mar 13;28(5):371–383. doi: 10.1007/s10552-017-0876-0

Table 5.

Association between cumulative average estrogen and progestin dose/potency and ovarian cancer risk adjusting for duration of OC use among ever OC users (1989-2013)

	Multivariate-adjusted models^a
	Cases	HR	95% CI	Cases	HR	95% CI
		Cumulative average estrogen dose^b
		< Median			≥ Median
Average progestin dose
< Median	48	1.00	(Ref.)	31	1.24	(0.77, 2.00)
≥ Median	20	0.91	(0.54, 1.52)	92	1.34	(0.92, 1.95)
		Cumulative average estrogen potency
		< Median			≥ Median
Average progestin potency⁴
< Median	34	1.00	(Ref.)	19	0.99	(0.56, 1.74)
≥ Median	55	1.16	(0.75, 1.80)	76	1.13	(0.74, 1.75)

Adjusted for age (months), calendar time, parity (number of pregnancies), tubal ligation (yes/no), breastfeeding duration (months), missing breastfeeding (yes/no), body mass index (kg/m²), duration of OC use (months)

Median values were updated at each follow-up cycle